Anebulo Pharmaceuticals, Inc. reported its financial results for the fiscal year ended June 30, 2024, on September 22, 2025. The company recorded a net loss of $(8.20) million for the year, an improvement from a net loss of $(11.73) million in fiscal year 2023.
Operating expenses saw a notable decrease, with research and development (R&D) expenses falling to $3.55 million from $5.60 million in the prior year, and general and administrative (G&A) expenses decreasing to $4.76 million from $6.18 million. Total operating expenses for the year were $8.31 million, down from $11.78 million in fiscal year 2023.
As of June 30, 2024, cash and cash equivalents were $3.09 million, a decrease from $11.25 million a year prior. The company also announced a two-year cooperative grant awarded in July 2024 from the National Institute on Drug Abuse (NIDA), providing up to approximately $1.9 million to support the intravenous selonabant development, with an initial tranche of $0.9 million already received. This non-dilutive funding is contingent on achieving specific milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.